The divestiture of Coflex and Paradigm Spine assets to Companion Spine for $21.4 million marks a strategic pivot to focus exclusively on high-margin core biologics.

Management successfully achieved a multi-year goal of self-sustainability, delivering positive net income, adjusted EBITDA, and cash flow through disciplined operational execution.

Performance in Q4 was impacted by the early closing of the Companion Spine deal, which removed approximately $2 million of revenue that was originally anticipated for the period.

The company has transitioned from a period of internal consolidation and manufacturing optimization to a phase of aggressive top-line growth pursuit.

Strategic differentiation is now centered on being a comprehensive partner in regenerative medicine, offering solutions across all five major orthobiologic categories.

Commercial reach is being expanded by doubling the regional sales force and increasing investments in the national accounts team to drive institutional adoption.

Full year 2026 revenue guidance of $95 million to $99 million accounts for the structural loss of divested hardware revenue and expiring license agreements.

Management expects organic biologics growth to accelerate throughout 2026 as the expanded sales force reaches full productivity and new products gain market traction.

The company anticipates maintaining positive free cash flow and does not foresee a need for additional outside capital due to a strengthened balance sheet.

Guidance assumes a 'melting ice cube' scenario for the remaining hardware business, with expected declines in the high teens as focus shifts to biologics.

Revenue from advanced wound care is expected to ramp in the second half of 2026 as the company transitions from OEM manufacturing to selling Xtant-branded products directly to hospitals.

The expiration of license revenue related to Q-code and amniotic membrane agreements creates a non-recurring headwind for the 2026 comparable periods.

A $1.3 million inventory charge in Q4 associated with the Cortera Fixation System launch impacted quarterly gross margins.

Hardware gross margins are being pressured by non-product costs, specifically charges for excess and obsolete inventory, which offset gains in the biologics segment.

The company utilized divestiture proceeds to reduce borrowings, resulting in a significantly cleaner capital structure heading into the new fiscal year.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expects Q1 biologics to be down low double digits due to the loss of Amnio product revenue, with hardware down approximately mid-teens.

Growth is expected to be back-half weighted as new sales reps ramp up and seasonality impacts the third quarter.

While the specific license revenue disappears, management believes the underlying business will recover as they shift to selling branded products into acute care settings.

The recovery in this segment is projected to begin in late Q2 or the second half of 2026.

Hardware currently serves as a 'table setter' for biologics sales in adult degenerative spine procedures.

Management is actively evaluating at what point the hardware business becomes a strategic distraction or an excessive drag on overall corporate growth.

Approximately 20% to 22% of the biologics business is expected to come from OEM channels.

The primary growth engine will be Xtant-branded products sold through the independent agent network, which was previously under-resourced during the sustainability phase.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.